XML 29 R20.htm IDEA: XBRL DOCUMENT v3.22.2.2
Segments
9 Months Ended
Oct. 01, 2022
Segment Reporting [Abstract]  
Segments SegmentsThe Company’s two reportable segments are U.S. and International. The Company’s products are primarily sold to orthopedists, musculoskeletal and sports medicine physicians, podiatrists, neurosurgeons and orthopedic spine surgeons, as well as to their patients. The Company does not disclose segment information by asset as the Chief Operating Decision Maker does not review or use it to allocate resources or to assess the operating results and financial performance. Segment adjusted EBITDA is the segment profitability metric reported to the Company’s Chief Operating Decision Maker for purposes of decisions about allocation of resources to, and assessing performance of, each reportable segment.
The following table presents segment adjusted EBITDA reconciled to (loss) income before income taxes:
Three Months EndedNine Months Ended
October 1, 2022October 2, 2021October 1, 2022October 2, 2021
Segment adjusted EBITDA
U.S.$19,543 $19,782 $43,467 $46,929 
International1,496 1,533 7,614 5,343 
Interest expense, net(9,894)(1,347)(10,922)(152)
Depreciation and amortization(18,780)(8,522)(43,643)(23,185)
Acquisition and related costs(6,319)(5,914)(20,292)(14,044)
Remeasurement gain on equity method investment23,709 23,709 
Restructuring and succession charges(575)(1,798)(2,847)(2,142)
Equity compensation(4,648)(5,938)(14,153)10,621 
Equity loss in unconsolidated investments(322)(419)(1,003)(1,320)
Foreign currency impact(581)(17)(1,122)47 
Impairment of goodwill(189,197)— (189,197)— 
Impairments related to variable interest entity— — — (7,043)
Other items(1,909)(511)(5,796)(2,816)
(Loss) income before income taxes$(187,477)$(3,151)$(214,185)$12,238